| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/12/2001 | WO2001024815A1 Plasminogen-like polynucleotides, polypeptides, and antibodies |
| 04/12/2001 | WO2001024814A1 Stabilized liquid polypeptide-containing pharmaceutical compositions |
| 04/12/2001 | WO2001024813A1 Use of tgf beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa |
| 04/12/2001 | WO2001024812A1 USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
| 04/12/2001 | WO2001024811A1 April receptor (bcma) and uses thereof |
| 04/12/2001 | WO2001024809A1 A method of treating erectile dysfunction |
| 04/12/2001 | WO2001024799A1 Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes, dna viruses and retroviruses |
| 04/12/2001 | WO2001024794A1 A method for the treatment of ocular oxidative stress |
| 04/12/2001 | WO2001024789A1 Agents for reducing cholesterol-uptake and liquid-uptake |
| 04/12/2001 | WO2001024785A2 Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| 04/12/2001 | WO2001024784A2 New use |
| 04/12/2001 | WO2001024782A2 Pharmaceutical agent for the treatment of cachexia and/or cardiogenic shock |
| 04/12/2001 | WO2001024772A1 Formulation for menopausal women |
| 04/12/2001 | WO2001024765A2 Antigenic modification of polypeptides |
| 04/12/2001 | WO2001024763A2 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| 04/12/2001 | WO2001024635A1 AsuE |
| 04/12/2001 | WO2001005420A8 SMALL PEPTIDES AND METHODS FOR DOWNREGULATION OF IgE |
| 04/12/2001 | WO2001000230A8 Drug composition containing lecithin-modified superoxide dismutase |
| 04/12/2001 | WO2000077190A3 Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt |
| 04/12/2001 | WO2000074723A3 Methods for the gene therapy of benign prostatic hyperplasia and medical agents therefore |
| 04/12/2001 | WO2000069454A8 Suppression of endogenous igfbp-2 to inhibit cancer |
| 04/12/2001 | WO2000066144A3 Monthly doses of glycopeptide antibiotics for treatment of streptococcus pneumoniae infections |
| 04/12/2001 | WO2000064938A3 Peptide homodimers or peptide heterodimers derived from interleukin 12 |
| 04/12/2001 | WO2000061755A3 Secreted human proteins |
| 04/12/2001 | WO2000046380A3 Fibroblast growth factor receptor-immunoglobulin fusion |
| 04/12/2001 | WO2000004891A3 Anti-ulcer composition |
| 04/12/2001 | WO2000000616A9 Marburg virus vaccines |
| 04/12/2001 | WO1999067283A3 Two-kinase domain mitogen- and stress-activated protein kinases and uses thereof |
| 04/12/2001 | WO1999051735A3 Mapkap kinase 2-inhibitors and the use thereof in anti-inflammatory therapy |
| 04/12/2001 | WO1997004099A3 Papillomaviruses, agents for detecting them and for treating diseases caused by such viruses |
| 04/12/2001 | US20010000241 A polynucleotide of either: (a) a polynucleotide encoding the SEQ ID NO:2; (b) a polynucleotide encoding a mature polypeptide encoded by the DNA contained in an ATCC deposit; a hybridizing polynucleotides; polypeptide receptor ligands |
| 04/12/2001 | DE19948269A1 New compounds as integrin antagonists useful for treating e.g. cardiovascular disorders, rheumatoid arthritis, kidney failure, stroke, cancer, osteoporosis, psoriasis or infection |
| 04/12/2001 | DE19948126A1 Pharmazeutisches Mittel zur Behandlung von Kachexie und/oder kardiogenem Schock A pharmaceutical composition for the treatment of cachexia and / or cardiogenic shock |
| 04/12/2001 | CA2645397A1 Formulation for menopausal women |
| 04/12/2001 | CA2406882A1 Diagnostic probes and therapeutics targeting upa and upar |
| 04/12/2001 | CA2388487A1 Tissue plasminogen activator-like protease |
| 04/12/2001 | CA2386722A1 Materials and methods for simplified aav production |
| 04/12/2001 | CA2386546A1 Adeno-associated viruses and uses thereof |
| 04/12/2001 | CA2386540A1 Novel carbamates and ureas |
| 04/12/2001 | CA2386533A1 Use of soluble costimulatory factor for tumor immuno-gene therapy |
| 04/12/2001 | CA2386480A1 A method of treating erectile dysfunction |
| 04/12/2001 | CA2386465A1 Compositions and methods for tumor-targeted delivery of effector molecules |
| 04/12/2001 | CA2386457A1 Inhibitors of the endothelin signalling pathway and .alpha.v.beta.3 integrin receptor antagonists for combination therapy |
| 04/12/2001 | CA2386383A1 Growth factor polypeptides and nucleic acids encoding same |
| 04/12/2001 | CA2386248A1 Il13 mutants |
| 04/12/2001 | CA2386239A1 Methods for identifying rna binding compounds |
| 04/12/2001 | CA2386237A1 Improved ricin-like toxins for treatment of cancer |
| 04/12/2001 | CA2386228A1 Stabilized liquid pharmaceutical compositions comprising tissue factor pathway inhibitor (tfpi) polypeptides |
| 04/12/2001 | CA2386199A1 Endozepine-like polypeptides and polynucleotides encoding same |
| 04/12/2001 | CA2386192A1 C-myc antisense-treated hematopoietic stem cell composition and method |
| 04/12/2001 | CA2386185A1 Fibrinolytically active polypeptide |
| 04/12/2001 | CA2385966A1 Pharmaceutical compositions of fibrinolytic agent |
| 04/12/2001 | CA2385961A1 Agents for reducing cholesterol-uptake and liquid-uptake |
| 04/12/2001 | CA2385864A1 Compositions and methods relating to the inhibition of casomorphin and gluteomorphin |
| 04/12/2001 | CA2385853A1 Design of high affinity rnase h recruiting oligonucleotide |
| 04/12/2001 | CA2385703A1 Plasminogen-like polynucleotides, polypeptides, and antibodies |
| 04/12/2001 | CA2385696A1 Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles |
| 04/12/2001 | CA2385551A1 Metal-binding compounds and uses therefor |
| 04/12/2001 | CA2385528A1 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| 04/12/2001 | CA2385313A1 Foams and compositions containing these foams |
| 04/12/2001 | CA2385220A1 Antisense compositions and cancer-treatment methods |
| 04/12/2001 | CA2385127A1 Novel hepatoma-derived growth factor-like proteins, polynulceotides encoding them and methods of use |
| 04/12/2001 | CA2385045A1 Ifn-alpha homologues |
| 04/12/2001 | CA2385032A1 G protein-coupled receptor up-regulated in prostate cancer and uses thereof |
| 04/12/2001 | CA2384696A1 Fibroblast growth factor-5 (fgf-5) is a tumor associated t-cell antigen |
| 04/12/2001 | CA2382859A1 Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization |
| 04/12/2001 | CA2379971A1 Hybrid matrices and hybrid matrix mixtures |
| 04/12/2001 | CA2379462A1 Human g-protein coupled receptor |
| 04/12/2001 | CA2354043A1 Methods for inhibiting osteoclast formation or methods for inhibiting bone resorption |
| 04/12/2001 | CA2350715A1 A method for the treatment of ocular oxidative stress |
| 04/12/2001 | CA2348780A1 Regulatory/unfolding peptides of ezrin |
| 04/11/2001 | EP1090992A1 NOVEL POLYPEPTIDE, cDNA ENCODING THE SAME AND UTILIZATION THEREOF |
| 04/11/2001 | EP1090991A1 Novel nicotinic acetylcholine receptor subunit, its isolation and use |
| 04/11/2001 | EP1090990A1 Human g-protein-coupled receptor |
| 04/11/2001 | EP1090989A1 Human g-protein-coupled receptor |
| 04/11/2001 | EP1090987A1 Cell cycle regulatory factor |
| 04/11/2001 | EP1090927A1 Polypeptide (scFv) for the detection and removal of CA19-9 antigen positive cells |
| 04/11/2001 | EP1090926A1 Human G-protein coupled receptor |
| 04/11/2001 | EP1090925A1 Human G-protein coupled receptor |
| 04/11/2001 | EP1090924A1 Tumor antigen peptides originating in cyclophilin b |
| 04/11/2001 | EP1090914A2 Processes and intermediates for manufacturing retroviral protease inhibiting compounds |
| 04/11/2001 | EP1090912A1 Amino acid derivatives and drugs containing the same as the active ingredient |
| 04/11/2001 | EP1090909A1 Novel inhibitors of prenylated pyrophosphate consuming enzymes |
| 04/11/2001 | EP1090645A2 Oral delivery of chemically modified proteins |
| 04/11/2001 | EP1090643A1 Remedies for hypercalcemic crisis |
| 04/11/2001 | EP1090640A2 Insulin analog formulations |
| 04/11/2001 | EP1090634A1 Agents for reducing cholesterol and lipid uptake |
| 04/11/2001 | EP1090625A2 Topical composition for the skin and use thereof |
| 04/11/2001 | EP1090300A1 Assay to indicate the presence of non-fertilisable ova |
| 04/11/2001 | EP1090294A1 Methods for determining presence of cancer in a sample by determining expression of an ssx gene, peptides derived from said ssx gene and ny-eso-1 gene, and uses thereof |
| 04/11/2001 | EP1090146A1 Uses of dna-pk |
| 04/11/2001 | EP1090133A2 Non-food crop plant bioreactor |
| 04/11/2001 | EP1090131A1 HUMAN GLYCOPROTEASE-LIKE PROTEINS AND DNAs ENCODING THESE PROTEINS |
| 04/11/2001 | EP1090130A1 Protein c derivatives |
| 04/11/2001 | EP1090128A1 Modified vitamin-k-dependent polypeptides |
| 04/11/2001 | EP1090127A1 Adh7 nucleotides |
| 04/11/2001 | EP1090122A1 Nucleic sequence and deduced protein sequence family with human endogenous retroviral motifs, and their uses |
| 04/11/2001 | EP1090118A2 Human signal peptide-containing proteins |
| 04/11/2001 | EP1090116A2 Transgenic non-human animal which comprises an inactive peg3 gene, and the use thereof |
| 04/11/2001 | EP1090115A2 Modularly constructed rna molecules having two sequence region types |